Trazodone and Anesthesia: Perioperative Interactions, Risks, and Clinical Management

What Is Trazodone and Why Does It Matter in the Perioperative Setting?

Trazodone is a serotonin antagonist and reuptake inhibitor approved by the FDA for major depressive disorder, and it is widely prescribed off-label at lower doses (25 to 100 mg) for insomnia. [1] Because roughly one in five adults presenting for elective surgery takes a psychotropic medication, anesthesiologists encounter trazodone regularly. [2]

Pharmacological Profile Relevant to Anesthesia

Trazodone's mechanism is unusually broad for a single agent. It inhibits the serotonin transporter (SERT), antagonizes 5-HT2A and 5-HT2C receptors, blocks alpha-1 adrenergic receptors, and has significant histaminergic (H1) antagonism. Each of these actions has a distinct consequence under general anesthesia.

Alpha-1 blockade produces vasodilation at baseline. Volatile anesthetics such as sevoflurane and desflurane independently reduce systemic vascular resistance by 15 to 30%, so the two mechanisms together can produce clinically significant intraoperative hypotension that is harder to correct than hypotension from either drug alone. [3]

H1 antagonism compounds the sedation produced by propofol, opioids, and benzodiazepines. Patients on trazodone may require meaningfully lower induction doses of propofol, although no large randomized trial has established an exact dose-reduction percentage.

Serotonin Transporter Inhibition and Opioid Co-administration

The SERT inhibition is the property most relevant to serotonin syndrome. Meperidine and tramadol are weak serotonin reuptake inhibitors themselves, and fentanyl has modest serotonergic activity. The combination of trazodone with any of these opioids shifts the patient's serotonergic tone upward. When a third serotonergic agent (such as nitrous oxide or an intraoperative MAOI) is added, the risk of meeting the Hunter Criteria for serotonin syndrome rises substantially. [4]

Serotonin Syndrome: Clinical Presentation and Perioperative Triggers

Serotonin syndrome is a drug-induced state of excess serotonergic activity characterized by the triad of altered mental status, autonomic instability, and neuromuscular abnormality. Onset can occur within minutes of drug administration, making it especially dangerous in the intraoperative or immediate postoperative period.

Hunter Criteria Applied to the OR Setting

The Hunter Criteria, validated in a cohort study by Dunkley et al. (2003), define serotonin syndrome as the presence of one of five neuromuscular findings in the context of a serotonergic drug: clonus (spontaneous, inducible, or ocular), agitation, diaphoresis, tremor, or hyperreflexia with agitation. [4]

In the anesthetized patient, many of these signs are masked. Emergence agitation, unexplained tachycardia (heart rate above 120 bpm), hyperthermia, and limb rigidity after extubation should all prompt the team to consider serotonin syndrome in a patient who was on trazodone and received meperidine or tramadol intraoperatively.

High-Risk Drug Combinations in the Perioperative Period

The following pairings carry the greatest documented risk when trazodone is on board:

• Meperidine (Demerol): the highest-risk opioid due to dual SERT inhibition and MAOI-like properties at higher doses
• Tramadol: SERT inhibition plus mu-opioid activity; often underestimated by nursing and pharmacy staff
• Linezolid: an antibiotic with reversible MAOI activity, sometimes used perioperatively for MRSA coverage
• Methylene blue: used intraoperatively during parathyroid and sentinel-node procedures; a potent MAOI that has triggered serotonin syndrome with SSRIs and trazodone [5]
• Ondansetron: 5-HT3 antagonism at therapeutic doses is unlikely to precipitate syndrome, but at high doses the pharmacology becomes less predictable

The FDA issued a Drug Safety Communication in 2016 specifically warning about serotonin syndrome when serotonergic psychiatric drugs are combined with methylene blue during surgical procedures. [5]

Treatment Protocol for Intraoperative Serotonin Syndrome

Immediate management steps include:

1. Discontinue all serotonergic agents.
2. Administer IV benzodiazepines (lorazepam 1 to 2 mg IV) for agitation and myoclonus.
3. Cyproheptadine 12 mg PO (or via NG tube) is the primary serotonin antagonist used clinically; repeat 2 mg every 2 hours if symptoms persist. [6]
4. Control hyperthermia aggressively; temperature above 41 C carries mortality risk.
5. Intubate if airway patency is at risk from rigidity.

Intraoperative Hypotension: Mechanisms and Management

Trazodone-induced alpha-1 blockade is dose-dependent. At doses above 200 mg/day, orthostatic hypotension is a well-documented adverse effect reported in trazodone's prescribing information, occurring in approximately 5% of patients in premarketing trials. [1] Under general anesthesia, baseline vasodilation is compounded by:

• Positive-pressure ventilation reducing venous return
• Volatile anesthetics (sevoflurane, desflurane, isoflurane) reducing peripheral vascular resistance
• Propofol's independent vasodilatory effect
• Neuraxial anesthesia (spinal or epidural) producing sympathetic blockade

Vasopressor Selection in Trazodone-Treated Patients

Because trazodone occupies alpha-1 receptors, phenylephrine (a pure alpha-1 agonist) may have a blunted pressor response. Clinical reports suggest that norepinephrine or vasopressin may be more reliable options for refractory intraoperative hypotension in this population, though head-to-head data specific to trazodone are lacking. [7]

Ephedrine, which works partly by releasing norepinephrine from sympathetic terminals, retains activity even with alpha-1 blockade because its mechanism is presynaptic. It may be a reasonable first-line bolus agent (5 to 10 mg IV) for mild trazodone-related hypotension.

Preoperative Blood Pressure Optimization

Patients taking trazodone above 150 mg/day who present with resting systolic blood pressure below 100 mmHg should have their anesthesiologist and prescribing clinician discuss whether a dose reduction or temporary hold is appropriate before elective surgery.

CNS and Respiratory Depression: Additive Sedation Risk

Trazodone's H1 antagonism and mild intrinsic sedative properties combine with opioids, propofol, benzodiazepines, and volatile anesthetics to deepen and prolong CNS depression.

Postoperative Respiratory Depression

A retrospective review published in Anesthesia and Analgesia found that patients on sedating antidepressants (including trazodone) had statistically higher rates of postoperative oxygen desaturation (SpO2 < 90%) in the PACU compared to non-users (adjusted odds ratio 1.6, 95% CI 1.1 to 2.4). [8] This finding suggests routine extended PACU monitoring for patients who have not held their trazodone before surgery.

Propofol Dose Considerations

No formal dose-finding randomized controlled trial has established a trazodone-specific propofol induction dose adjustment. However, the additive sedation rationale supports titrating propofol slowly to effect rather than using fixed-weight-based dosing. Target a bispectral index (BIS) value of 40 to 60 for induction and maintenance, using the monitor rather than the dose chart.

Impact on Emergence

Prolonged sedation from the trazodone-anesthetic combination may delay emergence. Surgeons and anesthesiologists should set realistic expectations for operating room turnover time. Ensuring residual neuromuscular blockade is fully reversed with sugammadex (200 mg IV for moderate block) or neostigmine before extubation reduces one confounding variable.

Should Trazodone Be Stopped Before Surgery?

This is the most common clinical question and has no universally agreed answer. The existing evidence base is largely consensus-driven.

The Case for a Preoperative Hold

The American Society of Anesthesiologists Task Force on Preoperative Evaluation does not mandate stopping trazodone before all procedures, but its 2017 practice advisory states: "The anesthesiologist should review all psychotropic medications and weigh the risks of continuation against the risks of withdrawal." [9] For trazodone, the relevant risks of continuation include the serotonin syndrome triggers and alpha-1-mediated hypotension outlined above.

A 24 to 72-hour hold before elective surgery accomplishes two goals:

1. It allows plasma trazodone concentrations to fall below the threshold where clinically meaningful alpha-1 blockade occurs (trazodone's half-life is 5 to 9 hours for the parent compound and 4 to 14 hours for its active metabolite, m-chlorophenylpiperazine). [1]
2. It removes a serotonergic agent from the equation before serotonergic opioids are introduced.

The Case Against Stopping

Abrupt discontinuation of trazodone in patients using it for depression may precipitate discontinuation syndrome, though this is less severe than with SSRIs or SNRIs due to trazodone's shorter half-life and distinct mechanism. For patients using trazodone at 25 to 50 mg purely for insomnia, the psychiatric risk of stopping is minimal.

Patients using trazodone for active, poorly controlled major depressive disorder face a different calculus. Destabilizing mood before surgery increases postoperative pain perception, delays discharge, and worsens patient-reported outcomes. [10]

Practical Decision Framework

The table below summarizes a risk-stratified approach:

| Trazodone Dose | Indication | Recommendation | |---|---|---| | 25 to 100 mg | Insomnia only | Hold 48 to 72 hours before elective procedure | | 100 to 200 mg | Depression, stable | Hold 24 to 48 hours; coordinate with prescriber | | 200 to 400 mg | Depression, active | Do not stop unilaterally; prescriber co-decision; use morphine or hydromorphone instead of meperidine/tramadol | | Any dose | Emergency surgery | Continue; inform anesthesiologist; avoid methylene blue and meperidine |

Trazodone and Alcohol: A Separate But Clinically Relevant Interaction

Patients frequently ask whether they can drink while taking trazodone. The answer is no, particularly in the perioperative window.

Pharmacodynamic Overlap

Both trazodone and ethanol are CNS depressants. Their combination produces additive sedation, impaired psychomotor function, and increased fall risk. A crossover pharmacokinetic study published in the 1980s demonstrated that trazodone co-administration with ethanol significantly worsened performance on cognitive and motor testing compared to either substance alone. [11]

Perioperative Implications

Patients who consume alcohol within 24 hours of surgery and are also taking trazodone arrive with a baseline of CNS depression that may lower their MAC (minimum alveolar concentration) for volatile anesthetics and reduce the propofol dose needed for induction. Anesthesiologists should ask specifically about alcohol use in all preoperative assessments, not only about prescription medications.

Chronic heavy alcohol use independently alters hepatic CYP3A4 activity, which is the primary enzyme responsible for trazodone metabolism. CYP3A4 induction by chronic alcohol could theoretically lower steady-state trazodone levels, while acute alcohol inhibition has the opposite effect. [1]

Regional Anesthesia and Trazodone

Neuraxial and peripheral nerve blocks avoid some of the serotonergic opioid exposure that makes general anesthesia riskier for patients on trazodone. A spinal or epidural technique using local anesthetics alone eliminates the opioid variable entirely.

Alpha-1 Blockade and Spinal Hypotension

Spinal anesthesia produces sympathetic blockade below the level of injection, lowering peripheral vascular resistance abruptly. In a patient already alpha-1-blocked by trazodone, the expected hypotensive response to spinal may be more pronounced and harder to treat with phenylephrine. Prophylactic vasopressors (norepinephrine infusion 0.05 to 0.1 mcg/kg/min) started before intrathecal injection may offer better hemodynamic stability than rescue boluses. [7]

Sedation for Regional Techniques

When patients on trazodone receive midazolam, propofol, or dexmedetomidine for comfort during awake regional procedures, the additive sedation risk applies. Starting at 25 to 50% of standard doses and titrating to effect is a reasonable starting point.

Special Populations

Elderly Patients

Adults over 65 metabolize trazodone more slowly; renal and hepatic clearance reductions prolong the half-life toward the upper end of the range (up to 14 hours for the active metabolite). [1] Postoperative delirium risk in elderly patients on trazodone is elevated both from the drug itself and from the anesthetic exposure. The American Geriatrics Society Beers Criteria 2023 list trazodone as a drug to use with caution in older adults because of its orthostatic hypotension and sedation risks. [12]

Patients With Obstructive Sleep Apnea

Trazodone may worsen upper-airway tone during sleep, a concern relevant to postoperative recovery. One small crossover trial (N=30) found that trazodone at 100 mg worsened the apnea-hypopnea index in patients with moderate OSA. [13] Patients with both OSA and trazodone use should have CPAP available in the PACU and on the ward postoperatively.

Pediatric Considerations

Trazodone is not FDA-approved for pediatric use. Its off-label use in adolescents for insomnia or depression is documented but limited. Pediatric anesthesiologists should apply the same serotonin syndrome and sedation principles as for adults, adjusted for weight-based pharmacokinetics.

Monitoring Recommendations for Trazodone-Treated Surgical Patients

Standard ASA monitors (ECG, pulse oximetry, non-invasive blood pressure, capnography, temperature) are required for all general anesthetics and should be applied with attention to the following trazodone-specific signals:

• Continuous blood pressure reading (arterial line preferred for cases expected to last more than 2 hours or for patients on doses above 200 mg/day)
• Temperature monitoring to catch early hyperthermia if serotonin syndrome is developing
• BIS or processed EEG monitoring to guide propofol dosing and detect prolonged emergence
• Extended PACU stay (minimum 90 minutes) for patients who did not hold trazodone preoperatively

Communication Between Prescribers and Anesthesiologists

Medication reconciliation errors are a leading cause of perioperative adverse events. A 2019 systematic review in BJA found that up to 40% of medication histories taken at preoperative assessment contained at least one error, and psychotropics were among the most commonly missed drug classes. [14]

Patients taking trazodone should inform their surgeon at the time of scheduling, not just at the preoperative visit. This allows:

• Adequate time to coordinate a hold decision with the prescribing psychiatrist or primary care physician
• Pharmacy review for additional serotonergic agents in the medication list
• Anesthesia planning that favors morphine or hydromorphone over meperidine or tramadol

"Perioperative medication management requires clear lines of communication among the surgeon, anesthesiologist, and the prescribing clinician. For serotonergic agents in particular, failure to communicate a hold decision can have life-threatening consequences," according to the 2022 ASA Guidelines on Perioperative Care. [9]

Key Takeaways for Clinicians

Trazodone's alpha-1 blockade, H1 antagonism, and SERT inhibition each create distinct hazards in the perioperative period. Intraoperative hypotension responds better to norepinephrine or vasopressin than to phenylephrine alone. Serotonin syndrome risk is highest with meperidine, tramadol, linezolid, and methylene blue. A 24 to 72-hour preoperative hold is appropriate for patients using trazodone solely for insomnia. For patients with active depression on doses above 200 mg/day, the hold decision must be made collaboratively with the prescribing clinician, and the anesthetic plan should substitute morphine or hydromorphone for serotonergic opioids.

Patients who have not held trazodone before surgery require extended PACU monitoring for at least 90 minutes with continuous SpO2, blood pressure every 5 minutes, and temperature checked at 30-minute intervals.